Gastroenterology
Volume 138, Issue 3 , Pages 958-968 , March 2010

Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

  • J. Joshua Smith

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • Department of Cell and Developmental Biology, Vanderbilt Medical Center, Nashville, TN
    • The Vanderbilt Medical-Scientist Training Program (Clinical Investigator Track), Vanderbilt Medical Center, Nashville, TN
    • ,
  • Natasha G. Deane

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • Department of Radiology and the Vanderbilt University Institute of Imaging Science, Vanderbilt Medical Center, Nashville, TN
    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Fei Wu

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Nipun B. Merchant

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Bing Zhang

      Affiliations

    • Department of Biomedical Informatics, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Aixiang Jiang

      Affiliations

    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Biostatistics, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Pengcheng Lu

      Affiliations

    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Biostatistics, Vanderbilt Medical Center, Nashville, TN
    • ,
  • J. Chad Johnson

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Carl Schmidt

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Christina E. Bailey

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Steven Eschrich

      Affiliations

    • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    • ,
  • Christian Kis

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Shawn Levy

      Affiliations

    • Department of Biomedical Informatics, Vanderbilt Medical Center, Nashville, TN
    • Vanderbilt Microarray Shared Resource, Nashville, TN
    • ,
  • M. Kay Washington

      Affiliations

    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Pathology, Vanderbilt Medical Center, Nashville, TN
    • ,
  • Martin J. Heslin

      Affiliations

    • Department of Surgery, University of Alabama School of Medicine-Birmingham, Birmingham, AL
    • ,
  • Robert J. Coffey

      Affiliations

    • Department of Cell and Developmental Biology, Vanderbilt Medical Center, Nashville, TN
    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Cancer Biology, Vanderbilt Medical Center, Nashville, TN
    • Department of Medicine, Nashville Veterans Affairs Medical Center, Nashville, TN
    • ,
  • Timothy J. Yeatman

      Affiliations

    • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    • ,
  • Yu Shyr

      Affiliations

    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Biostatistics, Vanderbilt Medical Center, Nashville, TN
    • Department of Cancer Biology, Vanderbilt Medical Center, Nashville, TN
    • ,
  • R. Daniel Beauchamp

      Affiliations

    • Department of Surgery, Vanderbilt Medical Center, Nashville, TN
    • Department of Cell and Developmental Biology, Vanderbilt Medical Center, Nashville, TN
    • Vanderbilt-Ingram Cancer Center, Vanderbilt Medical Center, Nashville, TN
    • Department of Cancer Biology, Vanderbilt Medical Center, Nashville, TN
    • Corresponding Author InformationReprint requests Address requests for reprints to: R. Daniel Beauchamp, D-4316 Medical Center North, Nashville, TN 37232-2730. fax: 615-343-5365

Received 11 August 2009 ,Accepted 4 November 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40:282–308
  3. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–3419
  4. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004;22:1797–1806
  5. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17:1349–1355
  6. Gray R, Barnwell J, et al. Quasar Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029
  7. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;CD005390
  8. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–3407
  9. Lafreniere R, Rosenberg SA. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst. 1986;76:309–322
  10. Poste G, Doll J, Fidler IJ. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A. 1981;78:6226–6230
  11. Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976;57:1199–1202
  12. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther. 2001;4:297–306
  13. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis. 2003;20:733–744
  14. Whitehead RH. The culture of tumour cells from human tumour biopsies. Clin Oncol. 1976;2:131–140
  15. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–2075
  16. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004;127(suppl):S51–S55
  17. Tukey JW. Tightening the clinical trial. Control Clin Trials. 1993;14:266–285
  18. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–548
  19. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–824
  20. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003;362:433–439
  21. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543–2546
  22. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol. 2006;24:4685–4691
  23. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14:822–827
  24. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  25. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004
  26. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564–1571
  27. Lin YH, Friederichs J, Black MA, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res. 2007;13:498–507
  28. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526–3535
  29. Garman KS, Acharya CR, Edelman E, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2008;105:19432–19437
  30. Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 2008;267:197–203
  31. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model (Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation). Carcinogenesis. 2000;21:757–768
  32. Kado S, Uchida K, Funabashi H, et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res. 2001;61:2395–2398
  33. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2:E7
  34. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004;36:1306–1311
  35. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582–1595

 The current address for Fei Wu is Bureau of Communicable Disease and Prevention, Missouri Department of Health and Senior Services, 930 Wildwood, PO Box 570, Jefferson City, Missouri 65102. The current address for Carl Schmidt is The Ohio State University Medical Center, College of Medicine, Division of Surgical Oncology, N-924 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210-1240.

 GEO accession number is GSE17538. Complete Minimum information about a microarray experiment (MIAME)-compliant datasets for analysis is available (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538).

 Conflicts of interest The authors disclose no conflicts.

 Funding This work was supported by the following grants from the National Institutes of Health: CA69457, DK52334, CA068485, and CA077839 (R.D.B.); TL1 RR024978 and CA106183 (J.J.S.); CA46413, CA95103, and CA084239 (R.J.C.); CA112215 (T.J.Y.); and CA126588 and CA128323 (N.G.D.). Other sources of funding include the Society of University Surgeons-Ethicon Scholarship Award (J.J.S.).

 J. Joshua Smith, Natasha G. Deane, Fei Wu, and R. Daniel Beauchamp contributed equally to this work.

PII: S0016-5085(09)01964-7

doi: 10.1053/j.gastro.2009.11.005

Gastroenterology
Volume 138, Issue 3 , Pages 958-968 , March 2010

Article Tools

* Image Usage & Resolution